Table 2.
Procedural biopsy characteristics for nondamaged and damaged groups
| Group | Number (n) | Sex (F) | Amount of Lidocaine Used, mL | Biopsy Weight Collected, mg | Number of Passes (3–5 Clips) | Operatorsa (n) | Participant Notes |
|---|---|---|---|---|---|---|---|
| Baseline Sample (Right Leg) | |||||||
| Nondamaged | n = 10 | 7 | 13.2 ± 2.8 | 252.0 ± 71.4 | 1.2 ± 0.4 | 3 | Previously had COVID-19 (2) |
| Damaged | n = 16 | 11 | 12.6 ± 2.5 | 256.6 ± 78.4 | 1.1 ± 0.3 | 2 | Previously had COVID-19 (1) |
| Post 7 Day Sample (Right Leg) | |||||||
| Nondamaged | n = 10 | 7 | 13.0 ± 2.8 | 234.5 ± 50.5 | 1.0 ± 0.0 | 2 | None |
| Damaged | n = 16 | 11 | 13.8 ± 2.8 | 214.9 ± 71.8 | 1.0 ± 0.0 | 3 | Complaint of discomfort during Bergström needle insertion (4), dizziness following procedure (1) |
aSame operator was used 80%–85% of the time. COVID-19, coronavirus disease of 2019.